Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)

Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for ...

Vertex: Buy At Ultracheap Multiples, Product Is Safe From AI

Vertex, Inc. is rated a Buy due to steady growth, margin expansion, recurring revenue, and high retention. Learn more about ...
StockStory.org on MSN

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2025 results , with sales up 9.5% year on year to $3.19 ...
The Motley Fool

Where Will Vertex Pharmaceuticals Be in 5 Years

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...